

10th April, 2013

NOTICE

PRIORITISATION OF ACTIVITIES AT CDSCO

To address the regulatory issues requiring greater attention in a timeframe manner for safeguarding and enhancing the public health by assuring the safety, efficacy and quality of drugs, cosmetics and medicinal devices, CDSCO has decided to give priority to the followings :

- Approval of New Drugs having direct impact on public health and of special relevance to Indian Health scenario.
- Monitoring the quality of drugs marketed in the country in coordination with the State Drug Control authorities.
- Examination of safety issues of marketed drug reported in the country or outside the country or through Pharmacovigilance Programme of India for taking decision on prohibition/restriction on use of such drugs.
- Registration of Ethics Committee.
- Monitoring of the clinical trials in the country
- Examination of reports of Serious Adverse Events occurring during Clinical Trial.
- Protecting rights, safety and well beings of the participating subjects in the clinical trials.


(Dr. G.N. Singh)
Drugs Controller General (India)

To

1. All Zonal/Sub Zonal Offices of CDSCO
2. All DDC(I)s/ADC(I)s at CDSCO HQ